Stem Cells for Treatment Resistant Bipolar Depression

July 20, 2021


This study aims to examine the safety and efficacy of Allogenic Mesenchymal Stem Cells (MSCs) as an adjunctive treatment of treatment resistant bipolar depression. Patients will be assigned into a treatment or a placebo group.

Patients who participate in this study will receive a single dose of MSCs or a placebo injection and will be followed up for 26 weeks after this. Half the patients will be randomly assigned to the MSCs-group, half the patients to the placebo group. Neither the patient nor the study team will know which group the patients are in.

Study Criteria: